Literature DB >> 2721542

Inhibitory effect of free fatty acids on plasma protein binding of disopyramide in haemodialysis patients.

T Horiuchi1, I Johno, T Hasegawa, S Kitazawa, M Goto, T Hata.   

Abstract

The plasma (or serum) protein binding of disopyramide (DSP) in five haemodialysis patients was studied using an ultrafiltration technique. There was an increase in the free fraction of DSP in the plasma on dialysis days in comparison to the levels on interdialysis days, which was associated with an elevation of the free fatty acid levels in the plasma together with the increase of the free fraction of DSP. The inhibitory effect of free fatty acids on DSP binding in an in vitro study was enhanced in proportion to their concentrations, and was shown to be due to competition at one binding site by experiments with oleic acid as a representative displacer. Certain endogenous organic acids, such as indoxyl sulphate, 2-hydroxyhippuric acid and hippuric acid, which are characteristically elevated in chronic renal failure, scarcely affected the protein binding of DSP. The findings indicate that free DSP should be monitored in patients with elevated plasma free fatty acid levels, such as those on haemodialysis therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2721542     DOI: 10.1007/BF00609191

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  30 in total

1.  DETERMINATION OF HEPARIN-INDUCED LIPOPROTEIN LIPASE ACTIVITY IN HUMAN PLASMA.

Authors:  J BOBERG; L A CARLSON
Journal:  Clin Chim Acta       Date:  1964-11       Impact factor: 3.786

2.  Altered drug binding due to the use of indwelling heparinized cannulas (heparin lock) for sampling.

Authors:  M Wood; D G Shand; A J Wood
Journal:  Clin Pharmacol Ther       Date:  1979-01       Impact factor: 6.875

3.  The plasma protein binding of basic drugs.

Authors:  P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

4.  Role of concentration-dependent plasma protein binding in disopyramide disposition.

Authors:  P J Meffin; E W Robert; R A Winkle; S Harapat; F A Peters; D C Harrison
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

5.  Experimental evidence for concentration-dependent plasma protein binding effects on the apparent half-lives of restrictively cleared drugs.

Authors:  J J Lima
Journal:  J Pharm Sci       Date:  1983-04       Impact factor: 3.534

6.  A pharmacokinetic analysis program (multi) for microcomputer.

Authors:  K Yamaoka; Y Tanigawara; T Nakagawa; T Uno
Journal:  J Pharmacobiodyn       Date:  1981-11

7.  Variability in heparin effect on serum drug binding.

Authors:  C A Naranjo; E M Sellers; V Khouw; P Alexander; T Fan; J Shaw
Journal:  Clin Pharmacol Ther       Date:  1980-10       Impact factor: 6.875

8.  Protein binding of disopyramide in liver cirrhosis and in nephrotic syndrome.

Authors:  H Echizen; S Saima; N Umeda; T Ishizaki
Journal:  Clin Pharmacol Ther       Date:  1986-09       Impact factor: 6.875

9.  The artifactual nature of heparin-induced drug protein-binding alterations.

Authors:  J E Brown; B B Kitchell; T D Bjornsson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

10.  Protein binding of ceftriaxone: comparison of three techniques of determination and the effect of 2-hydroxybenzoylglycine, a drug-binding inhibitor in uremia.

Authors:  C Fiset; F Vallée; M LeBel; M G Bergeron
Journal:  Ther Drug Monit       Date:  1986       Impact factor: 3.681

View more
  1 in total

1.  Tianeptine binding to human plasma proteins and plasma from patients with hepatic cirrhosis or renal failure.

Authors:  R Zini; D Morin; C Salvadori; J P Tillement
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.